This may be of particular importance, from a pharmacogenetic perspective to reduce ACE2 levels in those genetically likely to have high ACE2 levels prior to infection and to increase ACE2 levels following infection with COVID-19 with genotypes associated with low ACE2 activity and/or function. The gene discussed is ACE2; the disease is COVID-19.